Senti Biosciences ( (SNTI) ) has provided an announcement.
On February 23, 2025, Senti Biosciences announced the appointment of Jay Cross as the new Chief Financial Officer, effective March 3, 2025. Cross, with extensive experience in financial leadership roles, including at Sonnet BioTherapeutics, will oversee the company’s financial strategy and operations to support its growth and clinical development. This strategic hire, alongside the addition of Faraz Siddiqui as Senior Vice President of Technical Operations, is expected to bolster Senti Bio’s leadership team as it advances its clinical pipeline and manufacturing capabilities, particularly in oncology cell therapy.
More about Senti Biosciences
Senti Biosciences is a clinical-stage biotechnology company focused on developing next-generation cell and gene therapies using its proprietary Gene Circuit platform. The company aims to create therapies with enhanced precision and control, targeting challenging liquid and solid tumor indications with its lead program SENTI-202.
YTD Price Performance: 1.05%
Average Trading Volume: 2,467,720
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $18.59M
See more insights into SNTI stock on TipRanks’ Stock Analysis page.